The work of the CGT facility will span across multiple things – from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia
Published Date – 20 March 2025, 08:07 PM
Hyderabad: Hyderabad-based Bharat Biotech International Limited (BBIL), on Thursday announced the launch of country’s only vertically integrated, purpose-designed Cell and Gene Therapy (CGT) Infrastructure and Viral Vector Production Facility at Genome Valley.
Spread over 50,000 sft, the CGT facility will explore gene and cell therapies to tackle targetted gene expression, immune system modulation, and long-term cell survival. The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia, a press release said.
Dr Krishna Ella, executive chairman, Bharat Biotech, said, “Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today.”
Dr Raches Ella, chief development officer, Bharat Biotech, spearheading the CGT initiative, said: “Oncology and rare diseases’ treatment therapies are our key focus area and this facility will support a wide array of advanced therapies, including CD19 CAR T Cell Therapy for Blood cancers and Gene Therapy.”
Prof Krishanu Saha, University of Wisconsin, Madison, said that his lab has initiated a pioneering collaboration with Bharat Biotech to develop next-generation CAR (chimeric antigen receptor) cell therapies using AI.